Navigation Links
Sanofi-aventis Announces Good First-quarter 2009 Performance
Date:4/29/2009

ral expenses were 2.9% lower (5.6% at constant exchange rates), at euro 1,732 million. The ratio of selling and general expenses to net sales was 24.4%, versus 25.7% for the first quarter of 2008, due to the ongoing measures taken by sanofi-aventis to adapt to market conditions and the end of the commercialization of Copaxone(R) in North America.

Other current operating income and expenses showed net income of euro 148 million, against net income of euro 104 million in the first quarter of 2008. The 2009 figure includes the payment by Teva of a fee equal to 25% of the North American sales of Copaxone(R).

Operating income - current(1) was up 14.9% at euro 2,898 million. At constant exchange rate, the growth rate was 8.6%. The ratio of operating income - current to net sales improved by 4.4 points to 40.8%.

Net financial expenses were euro 44 million, against euro 17 million for the first quarter of 2008 (which included a gain on currency hedging). Interest expense on debt was euro 26 million, lower than the 2008 first-quarter figure of euro 44 million. Sanofi-aventis acquired Zentiva shares related to the public offer on March 11, 2009 for euro 1,197 million.

The effective tax rate was down 0.6 of a point at 29%, and was in line with the 2008 full-year figure.

The share of profits from associates was up 16.7% at euro 273 million. The share of after-tax profits from territories managed by BMS under the Plavix(R) and Avapro(R) alliance was 28.1% higher at euro 187 million, due to a good performance from Plavix(R) in the United States and a favorable dollar effect.

Minority interests increased by 5.2% to euro 121 million. The share of pre-tax profits paid to BMS from territories managed by sanofi-aventis rose by 3.6% to euro 115 million.

Adjusted net income excluding selected items(1) was euro
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
2. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
3. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
4. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
5. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
7. Sanofi-aventis Delivers 2008 Results Above Guidance
8. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
10. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... technology for deciphering mammograms is about to make the ... also enabling the much needed breathing time for the ... immense potential of the proposed system, which is capable ... indeed be a huge step towards enabling state-of-art breast ...
... that ban on smoking in public places may drastically cut ... Dr. Carl Bartecchi, a clinical professor of medicine at the ... a 27% decrease in hospital admissions for heart attacks for ... came into effect in Pueblo, Colorado in 2003. ...
... today clarified that so far no chikungunya deaths were ... Kuttamani said //that three death attributed to chikungunya were ... ,Mukundan, 71 at Vavallichira, Cherthala ded from chronic renal ... of Kollekkattu also died of natural causes. National Vector-borne ...
... prostate could be life threatening. September has been declared to ... prostrate cancer has been found to be the second most ... one out of every three men diagnosed with cancer, finding ... is especially important for African-American men with death rates for ...
... when a person’s immune system is damaged by alcohol ... seem to indulge in heavy drinking more than the ... drinking can quicken the advancement of end-stage simian immunodeficiency ... the case in humans infected with HIV. The October ...
... National Assembly for Wales to abolish car parking charges at ... burden. ,Welsh Secretary of the BMA, Dr Richard ... indirect tax on healthcare. These days, the vast majority of ... these people have to attend several times during treatment and ...
Cached Medicine News:Health News:No-smoking laws may reduce Heart attacks 2Health News:Chronic binge drinking can hasten HIV development 2Health News:Chronic binge drinking can hasten HIV development 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 2Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 4
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Strategy for ... ... SGMO ) announced today the publication of data,demonstrating that human immune ... treatment with zinc finger DNA-binding,protein nucleases (ZFN(TM)). The data suggest that ...
... mention ongoing FDA-approved HIFU clinical trials in the, ... and experience, CHARLOTTE, N.C., June 27 USHIFU, ... for prostate cancer,treatment in North and South America, announced ... featured a segment on high intensity focused,ultrasound (HIFU) for ...
Cached Medicine Technology:Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 3Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 4Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 5Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 6ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 2ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 3
1.0 mm diameter head, 0.75 mm deep bite....
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Optec vision tester....
Brightness acuity tester....
Medicine Products: